ABL DIAGNOSTICS : INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET AU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Company Overview: ABL Diagnostics specializes in developing software for medical data collection and processing, quality measurement of care, and genotyping diagnostics for infectious diseases, catering to healthcare professionals and researchers.
Shareholder Information: As of August 1, 2024, ABL Diagnostics has a total of 16,114,656 shares with 18,071,751 voting rights, including provisions for double voting rights for fully paid shares held by the same shareholder for two years.
Trade with 70% Backtested Accuracy
Analyst Views on ABLD
About the author

ETF Outflow Details: The ABLD ETF experienced the largest outflow, losing 700,000 units, which is a 34.1% decrease in outstanding units compared to the previous week.
Source of Information: The views expressed in the article are those of the author and do not necessarily represent the opinions of Nasdaq, Inc.
Shell Halts Biofuels Project: Shell Nederland Raffinaderij B.V. has decided to stop plans to resume construction of its biofuels facility in Rotterdam after determining it would not be competitive enough to meet market demands for affordable, low-carbon products.
Continued Investment in Energy Transition: Despite halting the biofuels project, Shell remains committed to the Netherlands, having invested 6.5 billion euros in various energy transition initiatives, including CO₂ storage and renewable hydrogen development.
Shell's Acquisition: Shell Nigeria Exploration has agreed to acquire TotalEnergies' 12.5% interest in the OML 118 Production Sharing Contract for $510 million, increasing its ownership from 55% to 67.5%, aligning with its goal of growing production by 1% annually until 2030.
TotalEnergies' Strategy Shift: The sale is part of TotalEnergies' strategy to optimize its Upstream portfolio by focusing on low-cost, low-emission assets, while also progressing projects like Ubeta to sustain gas supply in Nigeria.
Shell PLC Earnings Report: Shell reported first-quarter revenue of $69.234 billion, missing expectations, but adjusted earnings per ADS of $1.84 exceeded consensus. The company anticipates cash capital expenditures of $20-$22 billion for 2025 and stable production levels for the second quarter.
Analyst Outlook: RBC Capital Markets analyst Biraj Borkhataria maintains an Outperform rating on Shell, citing a strong balance sheet and ongoing share repurchase program that should enhance long-term earnings growth. He also notes planned divestments in Nigeria and the Chemicals division as positive steps for cost reduction and profitability improvement.
First Quarter Results: Shell plc reported a revenue of $69.234 billion, which fell short of expectations, but adjusted earnings increased by 52% to $5.58 billion, and net income rose significantly to $4.78 billion. The company also announced a $3.5 billion share buyback program and declared a dividend of $0.358 per share.
Future Guidance: For the second quarter of 2025, Shell expects production levels to be lower than previous quarters, with Integrated Gas production projected at 890 – 950 thousand boe/d and Upstream at 1,560 – 1,760 thousand boe/d. Additionally, corporate adjusted earnings are anticipated to be a net expense of $400 – $600 million.
Production Outlook Revision: Shell PLC has lowered its first-quarter production guidance for Integrated Gas and Upstream segments due to unplanned maintenance and the completion of a divestment, leading to a decrease in expected output across various categories.
Financial Adjustments and Stock Performance: The company has raised its cost reduction target and plans to increase shareholder distributions while experiencing a 4.80% drop in stock price during premarket trading.










